Low-dose clozapine improves dyskinesias in Parkinson's disease

Neurology

Volumn 48, Issue 3, 1997, Pages 658-662

  Durif, F ^a,c   Vidailhet, M ^b   Assal, F ^b   Roche, C ^a   Bonnet, A M ^b   Agid, Y ^b  

^a Fontmaure Hospital   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Hopital Fontmaure   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CLOZAPINE; DOMPERIDONE; LEVODOPA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DYSKINESIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR DYSFUNCTION; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030941117     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.3.658     Document Type: Article

References (46)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth, 1982:96-122.
2. Nutt JG. Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson's disease. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. Mt. Kisco, NY: Futura Publishing, 1992:281-314.
3. Muenter MD, Sharpless NS, Tya GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
4. Lhermitte F, Agid Y, Signoret JL, Studler JM. Les dyskinesies de "début et fin de dose" provoquées par la L-DOPA. Rev Neurol 1977;133:297-308.
5. Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesia, possible treatment by increasing the daily doses of levodopa. Arch Neurol 1978;35:261-263.
6. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiology. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth, 1982:123-135.
7. Pourcher E, Bonnet AM, Kefalos J, Dubois B, Agid Y. Effects of ethybenztropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease. Mov Disord 1989;4: 195-201.
8. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-1858.
9. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesias by propranolol in Parkinson's disease. Neurology 1996;46:1548-1551.
10. Klawans HL, Weiner WJ. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1974;37:427-430.
11. Lees AJ, Lander CM, Stern GM. Tiapride in levodopa-induced involuntary movements. J Neurol Neurosurg Psychiatry 1979; 42:380-383.
12. Criswell HE, Mueller RA, Breese GA. Clozapine, antagonism of D-1 and D-2 dopamine receptor-mediated behaviors. Eur J Pharmacol 1989;159:141-147.
13. Murray AM, Waddington JL. The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioral indices. Eur J Pharmacol 1990;186:79-86.
14. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
15. Seeman P. Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992;7:261-284.
16. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-754.
17. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(suppl B):47-52.
18. Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985;71: 176-185.
19. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
20. Kane JM, Lieberman J, Pollak S, Safferman A. Clozapine and tardive dyskinesia: prospective data. Schizophr Res 1991;4: 364-365.
21. Friedman JH, Lannon MCL. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989;39:1219-1221.
22. Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990;5:239-242.
23. Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991;41:1699-1700.
24. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7:125-131.
25. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45: 432-434.
26. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73:295-297.
27. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990;5:225-229.
28. Fisher PA, Baas H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neural Transm 1990;2:233-238.
29. Jansen ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994;89:262-265.
30. Linazasoro G, Marti Masso JF, Suarez A. Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993;8:171-174.
31. Gomez Arevalo GJ, Gershanik OS. Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 1993;8:349-354.
32. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43:1551-1555.
33. Bennett JP, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-414.
34. Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:117-164.
35. Agid Y, Pollak P, Bonnet AM, Signoret JL, Lhermitte F. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet 1979;i:570-572.
36. Marconi, R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesia in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
37. Goetz CG, Stebbins GT, Shale HM, et al. Evaluation of intra-and interrater reliability in dyskinesia rating scale for Parkinson's disease. Mov Disord 1993;8:416.
38. Factor SA, Brown D, Molho ES, Podskalny GD. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44:544-546.
39. Kempster PA, Frankel JP, Stern GM, Lees AJ. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:1004-1007.
40. Agid Y, Bonnet AM, Ruberg M, Javoy-Agid F. Pathophysiology of levodopa-induced abnormal involuntary movements. In: Casey D, Chase TN, Christensen VN, Gerlach JE, eds. Dyskinesia: research and treatment. Berlin: Springer-Verlag, 1985: 145-159 (Psychopharmacology, suppl 2).
41. Mouradian MM, Heuser IJE, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
42. 3H) spiperone binding. Brain Res 1986;379:294-299.
43. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
44. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Differential effects of D-1 and D-2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990;40:927-933.
45. Gomez-Mancilla B, Bedard BJ. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413.
46. Kuhar MJ. Neuroanatomical substrates of anxiety: a brief survey. Trends Neurosci 1986;9:311-313.